Category: Strain Optimization Services

Optimizing Production of Biobased Speciality Chemicals with Lygos

Posted on by Ena Cratsenburg

Strain development program aims to accelerate efforts to create sustainable chemicals

Today we’re pleased to announce our multi-product research and development collaboration with Lygos. This partnership is designed to optimize and scale production of sustainable specialty ingredients that can replace toxic petrochemistry, reclaim local manufacturing, and advance industrial bio-innovation.

Together, we plan to advance two research and development programs over the course of approximately two years. Lygos’ organic acid targets are used to produce biodegradable formulations and polymer-based products used in consumer, agricultural and industrial markets. We at Ginkgo will leverage our extensive expertise in strain development and metabolic engineering as we work to rapidly design and optimize microorganisms that can convert low-cost sugar to high-value chemicals. This in turn can provide a more sustainable alternative to the traditional industrial chemicals that are made from petroleum-derived feedstock.

Creating sustainable biomanufacturing solutions

Many specialty organic acids rely on environmentally damaging and costly production processes. We’re excited to be working with Lygos to replace some of those harmful production methods with sustainable, environmentally friendly biomanufacturing processes. Ginkgo is committed to creating solutions that are better for the planet, and this partnership with Lygos will help advance our initiatives around climate sustainability while supporting domestic manufacturing and technology development.

“Lygos and Ginkgo have been at the forefront of this field, enabling customers to create sustainable products that can help solve the world’s environmental challenges and improve everyday products,” said Eric Steen, PhD, CEO at Lygos.  “The new partnership will enable us to augment our development timelines, allocate more research and development, and accelerate our product commercialization programs.”

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

High Throughput Screening for Designing Novel CAR-T Cell Therapies

Posted on by Shawdee Eshghi

Pooled screening platform for discovering the next generation of CARs

Image of a poster containing CAR-T data

Ginkgo is proud to present a poster this Friday, November 11 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The poster highlights our Foundry-enabled methods for large-scale, combinatorial library design and screening of chimeric antigen receptor (CAR) domains for improved persistence. The ability to screen hundreds of thousands of CAR designs in primary human T cells can enable discovery of variants with desired characteristics. This capability has the potential to discover CAR-T therapies that are effective against solid tumors.

CAR-T cell therapies show tremendous promise for the treatment of cancer. But so far, their use has been limited to targeting blood cancers, as CAR-T has failed to show consistent efficacy in treating solid tumors, which represent approximately 90% of adult human cancers. Part of the challenge when applying CAR-T therapies to solid tumors lies in T cell exhaustion, a state of dysfunction arising from excessive antigen stimulation in the immunosuppressive environment of a solid tumor.

Therapeutic outcomes of CAR-T cell therapies—including CAR-T persistence—correspond to T cell behaviors driven by signaling cascades that are triggered by the intracellular domains (ICD) of CARs. Until now, technical constraints in high throughput screening have made the systematic design and testing of novel ICD combinations that drive more favorable T cell phenotypes onerous. New data we are presenting at SITC will demonstrate that our high throughput screening method enables massively parallel testing of CAR designs and has led to the discovery of new ICD combinations that outperform the canonical CD28-CD3z and 4-1BB-CD3z combinations.

Discovering next generation CAR-T cell therapies

Our platform for cell programming enables synthesis and screening of diverse libraries of genetic constructs to explore biological space. Applying these capabilities to the design of CARs enables screening of hundreds of thousands of possible combinatorial variants of different CAR ICDs. The data we will present at SITC will show how this method could be used to screen for variants with increased persistence in a serial tumor rechallenge assay. As an enabling platform company, we can leverage our full stack of mammalian cell engineering expertise and capabilities to enable the high throughput screening of CAR-T cells to discover and optimize next generation therapeutic candidates for our partners.

While innovation in CAR-T cell therapies continues to grow at a dramatic pace, CAR-T is still a relatively new modality whose potential is just beginning to be fully explored. With large scale screening and automation, we have created a tool we believe can dramatically expand the variety and functionality of CAR domains so that our partners can build therapies targeted for particular tumor environments.

“We’ve only seen a small sliver of what revolutionary modalities like CAR-T can achieve in terms of patient outcomes. Being able to explore broader design space for this powerful technology can help unlock new potential in solid tumor treatment, inflammatory and autoimmune diseases, and beyond.” said Arie Belldegrun, Executive Chairman and Co-Founder of Allogene Therapeutics and Kite Therapeutics and member of the Board of Directors for Ginkgo Bioworks. “The scale of Ginkgo’s platform helps to enable discovery and innovation in this important arena.”

You can view our poster at SITC. To register, visit www.sitcancer.org/2022.

Presentation details:

Date & Time: Friday, November 11, 2022 at 9 am – 8:30 pm, EST
Title: Pooled screening platform for discovering the next generation Chimeric Antigen Receptors
Presenting Author: Taeyoon Kyung, PhD, Senior Mammalian Engineer, Ginkgo Bioworks
Poster Number: 242

Click here to speak with our team and learn more about leveraging our platform.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Enhancing Biomaterials with Bolt Threads

Posted on by Jason Kelly

The new program builds on our existing work with Bolt Threads optimizing their b-silk protein

Today we’re announcing a multi-project collaboration with Bolt Threads, a biotechnology company creating the next generation of advanced materials, to increase the production efficiency and performance of their portfolio of products and to develop additional novel proteins for their biomaterials. The first program in this collaboration aims to optimize the production efficiency of Bolt’s Mylo™ material, a leather alternative material made out of mycelium, the underground root-like system of fungi.

Mylo is an animal-free, sustainable alternative to leather grown from mycelium 

Through Bolt Threads’ production process, mycelium grows into a foamy layer that, once harvested, can be dyed and processed into sheets of material that can be customized to desired size, color, shape, and thicknesses. Mylo can be used in footwear, handbags, wallets, phone cases, and other products; the product is already used by brands like adidas, Stella McCartney, GANNI, and lululemon. Unlike traditional leather made from animal hides, mycelium leather does not rely on raising livestock, and unlike synthetic leather, Mylo isn’t petroleum-derived.

Through this collaboration, we aim to increase the growth rate of Bolt’s mycelium strain, lowering the overall production costs of Mylo. This collaboration also marks an expansion of our current work together, as we are already optimizing the sustainability, efficiency, and cost-effectiveness of Bolt Threads’ b-silk™ protein manufacturing process.

Over the last few years, the largest fashion brands worldwide and the textiles industry have collectively recognized the need to develop more sustainable and low-footprint materials. Bolt Threads is at the forefront of this shift, and Mylo represents this future. We are excited to leverage our Foundry and Codebase to help drive down the cost of producing Mylo, making the product more accessible to a variety of markets where innovative and exciting alternative materials can be used.

“Ginkgo’s expertise in engineering biology has enabled us to accelerate our work transforming the clean beauty and personal care industries with b-silk protein,” said David Breslauer, Co-Founder and Chief Technology Officer at Bolt Threads. “We are thrilled to be partnering with them again to optimize the production of our mycelium technology which will help make Mylo more accessible to consumers and brands alike.”

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Ginkgo Expands Agricultural Biologicals Division, Closes Deal with Bayer

Posted on by Jason Kelly

Today, Ginkgo closed our deal with Bayer, expanding our ag biologics division.

As a result of the close:

  • The nitrogen fixation and R&D platform assets of Joyn Bio are now integrated into Ginkgo.
  • Bayer’s West Sacramento Biologics Research & Development site and platform is now a part of Ginkgo’s ag biologics division.
  • Ginkgo becomes a multi-year strategic partner with Bayer to develop biological solutions in areas such as nitrogen optimization, carbon sequestration, and next generation crop protection.
  • Bayer will continue work to optimize Joyn Bio’s nitrogen fixation technology, aiming to complement synthetic fertilizers going forward.

Today we’re pleased to announce the beginning of our multi-year strategic partnership with Bayer to accelerate research and development of biological products for agriculture. The transaction includes the divestment of Bayer’s West Sacramento Biologics Research & Development site and its internal discovery and lead optimization platform; these assets are now integrated into Ginkgo.

Through this deal, the nitrogen fixation and R&D platform assets of Joyn Bio—the joint venture created by Bayer and Ginkgo Bioworks in 2017—will be fully integrated into Ginkgo. This will enable the continued advancement of Joyn Bio’s innovative nitrogen fixation platform. As part of the agreement, Bayer retains the right to commercialize the technology to complement synthetic fertilizer use in the coming years.

Sustainable, climate-smart and innovative agricultural solutions

Bayer is now the first major partner of Ginkgo Bioworks’ expanded agricultural biologicals platform. The new collaboration will be focused on important programs in the areas of crop protection, nitrogen fixation, and carbon sequestration to identify next generation biologicals that provide clear benefits to growers.

“Biological solutions play a critical role in the agricultural innovation ecosystem, and we see tremendous opportunity for these products to add even more value for agriculture in the future,” said Dr. Robert Reiter, Head of R&D at Bayer’s Crop Science Division. “[Bayer’s] open innovation approach will accelerate the product pipeline and will make sure that we bring high-quality biological solutions and innovative technologies to the market faster.”

Microbial derived products for agriculture

Here at Ginkgo, we’re committed to harnessing the power of programmable biology to enable sustainable food production and food security worldwide. We aim to develop and advance agricultural microbial solutions across crops and geographies through broad, fully-enabled technical platforms that address diverse market needs. We will work independently with different partners in the discovery of microbial derived products for agriculture.

We look forward to partnering with Bayer and other innovative companies to bring more applications on to Ginkgo’s expanded agricultural biologicals platform so that growers worldwide can develop breakthrough products.

What will you grow with Ginkgo?

Find the full press release here along with all of the latest news from the Ginkgo team.

This blog post contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Ginkgo’s expectations regarding its ability to expand its platform capabilities in agricultural biologicals through the transaction and the expected outcomes and benefits of the transaction. These statements are subject to risks and uncertainties as described in the “Risk Factors” section of Ginkgo’s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 15, 2022 and other documents filed by Ginkgo from time to time with the SEC. Actual events and results could differ materially from those contained in the forward-looking statements.

Optimizing Crucial Drug Manufacturing of APIs with Merck

Posted on by Cindy Chang

Ginkgo to engineer key biocatalytic enzymes for potential use in Merck’s drug manufacturing processes

Today, Ginkgo is proud to announce a collaboration with Merck to optimize the manufacture of active pharmaceutical ingredients. The aim is to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient (API) manufacturing efforts. Through this collaboration, we will leverage our extensive experience in cell engineering and enzyme design, along with our capabilities in automated high throughput screening, manufacturing process development/optimization, bioinformatics and analytics to deliver optimal strains for expression of targeted biocatalysts.

Biocatalysis is a sustainable and effective alternative to some steps in industrial chemical synthesis

Enzyme biocatalysts can reduce costly synthesis and purification steps, thereby decreasing production costs. Through this collaboration, we aim to optimize several biocatalysts by leveraging our world-class proprietary fungal strains, cell line development, enzyme engineering and optimization, and multiomics expertise.

“Ginkgo’s fungal strains present a major opportunity for improving biocatalysis. E. coli is currently the mainstay host for expressing enzymes, but a large number of enzymes will not express properly in E. coli, and those that do express in E. coli may have better homologs that only express in fungal strains,” said Behzad Mahdavi, our Senior Vice President of Biopharma Manufacturing and Life Sciences Tools. “This enzyme optimization project with Merck has the potential to help reduce the cost of goods and enable a more robust supply chain for APIs.”

Merck is a pioneer in biocatalysis, improving manufacturing of crucial medicines. We’re thrilled to be partnering with Merck and to be leveraging our platform capabilities for improved enzyme activity and production. Ginkgo’s platform model enables us to identify improved enzymes and develop powerful fungal strains and fermentation processes for enzyme manufacturing, empowering downstream API production for our customers.

Under the terms of the collaboration, Ginkgo will earn an upfront research and development fee and is eligible for success-based research and development milestone payments. In addition, Ginkgo is eligible to earn commercial milestone payments for each of a specified number of biocatalysis targets, which have the potential to total, in the aggregate, up to $144 million. To learn more about Ginkgo’s work in enzyme discovery, visit this webpage and talk to our team today.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Developing Synthetic Biotics for Gout with Synlogic

Posted on by Patrick Boyle

Ginkgo and Synlogic announce the second drug candidate—a treatment for gout—in their partnership to develop synthetic biotics

Last November, we announced that SYNB1353, an engineered strain of the probiotic bacteria E. coli Nissle (EcN) designed and developed through a collaboration between Ginkgo and Synlogic, was to be nominated for investigational new drug (IND) status with the U.S. Food and Drug Administration (FDA). This would mark the first medicine developed on Ginkgo’s platform to enter IND-enabling studies but just the beginning of our work with Synlogic to create living medicines.

Today, we’re pleased to share Synlogic’s announcement of SYNB2081, a new drug candidate developed in partnership between our two companies for the treatment of gout.

Addressing unmet needs for patient care

Gout is a complex form of inflammatory arthritis that occurs when excess uric acid in the body forms crystals in the joints. Patients experience a range of symptoms, including intense joint pain, inflammation and redness, and limited range of motion in the affected joints. Unfortunately, current treatment options present limitations in both safety and efficacy, highlighting a need for new approaches.Gout is also a recognized risk factor in chronic kidney disease (CKD).

SYNB2081 is a synthetic biotic designed to lower uric acid for the treatment of gout. We’re honored to work with the Synlogic team in this pioneering next step to potentially help patients living with gout. As we’ve seen the Synlogic pipeline develop the past year, we’re eager to continue supporting Synlogic in generating additional therapeutic candidates.

SYNB2081 is named after one of the largest and best-preserved Tyrannosaurus rex specimens in the world. Nicknamed “Sue,” the specimen is housed at the Field Museum in Chicago and is officially named FMNH PR 2081. Data from “Sue” suggests that dinosaurs like the Tyrannosaurus rex suffered from gout much in the same way as other reptiles and birds do.

What if we could program microbes to act as medicine?

“With our second drug candidate into clinical development, this not only demonstrates the value of combining Ginkgo’s Codebase with our Synthetic Biotic platform, but also highlights the potential to develop Synthetic Biotics across a range of diseases, giving us the potential to provide meaningful new treatment options to patients in need,” said Dr. David Hava, Chief Scientific Officer, Synlogic.

The advancement of SYNB2081 and SYNB1353 are clear indicators of the transformative platform Synlogic has created to power new medicines through synthetic biology.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Scaling Production of Cultured THCV with Cronos Group

Posted on by Jason Kelly

Cronos and Ginkgo Announce Achievement of THCV Equity Milestone

Today, we’re excited to announce an achievement in our partnership with Cronos Group, an innovative global cannabinoid company. Together, we have hit the third target productivity milestone in our partnership to produce eight cultured cannabinoids. Using our platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos’ innovation pipeline and commercialization strategy.

Our partnership with Cronos launched in 2018, with the goal of accessing rare molecules in the cannabis plant to create innovative and differentiated products that would otherwise be cost-prohibitive. The program combines Cronos’ deep understanding of the biological structure and function of cannabinoids with our vast experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture and more.

Producing cultured cannabinoids at industrial scale

“Continuing to hit these productivity milestones in partnership with Ginkgo fuels our innovation pipeline focused on creating borderless products utilizing rare cannabinoids that amplify and differentiate the consumer experience,” said Mike Gorenstein, Chairman, President and CEO of Cronos. “We are excited about the possibilities that THCV is expected to give us and look forward to getting more products with rare cannabinoids into market.”

Working with Cronos to develop innovations in cannabis is an opportunity for us to apply synthetic biology in a way that is helping bring the cannabis industry forward and make a real impact on its market and the customers it serves. The progress we’ve made thus far in our collaboration is a true testament to both the potential of synthetic biology and the world-class teams at Cronos and Ginkgo.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Unlocking the Potential of Expression Systems for Medicines with Novo Nordisk

Posted on by Jason Kelly

 

Novo Nordisk will leverage Ginkgo’s Foundry and Codebase to create novel expression hosts for its pharmaceutical products.

Hundreds of millions of people currently live with diabetes, obesity, and other serious chronic diseases, putting a strain on individuals, families, and healthcare systems. More effective medicines could improve treatment options for these people. — Today, we announced that Novo Nordisk, a leading global healthcare company, will leverage Ginkgo’s cell programming platform to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of their biological medicines for chronic diseases.

What if you could grow medicines?

It’s an honor to work with partners like Novo Nordisk that not only have an incredible range of critically important products, but that also provide us with the opportunity to do meaningful work that could help so many patients. At Ginkgo, we are always on the lookout for projects that will have an outsized impact on people’s lives and well-being. We’re excited to be working with Novo Nordisk in our efforts to use biology to create better medicines for patients with chronic diseases.

The work aims to expand and improve the treatment options available for the millions of people with chronic diseases.

“Novo Nordisk is constantly pushing the boundaries for innovative tools to bring new treatments to people living with diabetes and other serious chronic diseases,” said Brian Vandahl, Senior Vice President, Global Research Technologies, Novo Nordisk. “Using synthetic biology and the reprogramming of expression system genomes, we have the potential to engineer biological systems that will expand the chemical space of biological medicines.”

Under the terms of the partnership, Ginkgo and Novo Nordisk will launch a multi-year collaboration. Ginkgo will receive an upfront R&D fee and is eligible to receive milestone payments as the parties advance in the collaboration.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Expanding Our Platform Capabilities in Agricultural Biologicals and Launching Flagship Partnership with Bayer

Posted on by Anna Marie Wagner

Announcement Highlights:

  • Planned transaction expands Ginkgo’s horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to allow access to customers of all sizes in the agriculture industry
  • Under the proposed transaction, Ginkgo to acquire Bayer’s West Sacramento agricultural biologicals site and team, adding a 175,000 square-foot R&D facility with pilot scale fermentation, formulation, and greenhouse facilities, along with access to Bayer’s large agricultural strain collection
  • Joyn Bio, the joint-venture between Ginkgo and Leaps by Bayer formed in 2017, to be integrated into the parent companies, with the core technology platform becoming part of Ginkgo’s platform and key products being advanced by Bayer in a new collaboration
  • Bayer to be an anchor customer of Ginkgo’s agricultural biologicals offering, signing a follow-on multi-year platform collaboration deal to enable continued development of Joyn Bio’s flagship nitrogen fixation program and launching new programs in fields including next-generation crop protection and carbon sequestration

We’re excited to announce plans to significantly expand our platform capabilities in agricultural biologicals from discovery to field. These capabilities will be built through a series of transactions; Ginkgo will acquire Bayer’s 175,000 square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform. Ginkgo will also integrate the R&D platform assets from Joyn Bio, a joint-venture between Ginkgo and Leaps by Bayer formed in 2017. Bayer will be the anchor agricultural customer of Ginkgo’s expanded platform, entering into a significant new multi-year collaboration which will focus on the advancement of Joyn’s marquee nitrogen fixation program as well as new programs in areas such as crop protection and carbon sequestration.

While Ginkgo will continue to evaluate the operating expenditures required to launch and scale its expanded agricultural capabilities following these transactions, it is expected that the cash proceeds from this multi-year collaboration with Bayer may significantly offset such anticipated expenditures. The proposed transactions are projected to close before the end of 2022, pending the finalization of definitive agreements and subject to regulatory approvals.

Agricultural biologicals are a rapidly growing category of solutions that offer tremendous sustainability and performance benefits. Against the backdrop of rising fertilizer costs and novel pest and disease threats, growers are calling for new agriculture solutions that can increase yields while decreasing their environmental footprint. While chemical and plant trait solutions have long been the dominant solutions on the market, demand for biologicals has increased dramatically.

Bayer, Ginkgo, and Joyn share a common vision, which is to enable biological products to be a critical part of the solution to the world’s greatest agricultural and environmental challenges. We are incredibly impressed by the success of the Joyn team and the deep expertise of Bayer’s West Sacramento R&D team and are thrilled to have them join Ginkgo as we build deep end-to-end capabilities in ag biologicals on top of our large scale horizontal platform. We believe we’re bringing together the most innovative minds in agriculture with the experience of a team that has brought several effective biological products to market for Bayer — opening this platform up to the world has the potential to truly revolutionize the field.

Bayer has long been committed to expanding its product offerings to benefit growers around the world. In recent years, the company has made a strategic decision to focus on becoming the preferred research, development, and commercial partner in the biologicals segment, while leveraging an “open innovation” model to be able to partner broadly with disruptive discovery companies.

Through this agreement, Bayer is committing to a significant multi-year collaboration, advancing multiple programs including a marquee nitrogen fixation program as well as a suite of other programs in areas such as next-generation crop protection and carbon sequestration.

“Biological solutions will play a critical role in the agricultural innovation ecosystem, and we see tremendous opportunity for biologicals to add even more value for agriculture in the future because they are effective and offer environmental benefits that producers want,” said Bob Reiter, Head of R&D for Bayer Crop Science. “Bayer is moving to strengthen its product development and commercial positioning through strategic research partnerships for new product development, and we are excited to deepen our relationship with Ginkgo, which we expect to be a key partner for many years to come.”

Over the last five years, Joyn has developed a new class of microbial solutions in partnership with Bayer and Ginkgo. Through this transaction, Joyn’s product concepts will be advanced by Bayer, with a particular focus on its nitrogen fixation program, while the platform assets and supporting team members will be integrated into Ginkgo as the company expands its support for agricultural biologicals.

Ginkgo will offer these new platform capabilities to a wide variety of customers in the agriculture space.

Ginkgo expects to provide a full stack of services in this field. This extension of our platform will allow companies of all sizes to access best-in-class lab-to-field translation expertise, greenhouse capacity, formulation capabilities, and pilot fermentation.

“With support from Ginkgo and Bayer, Joyn Bio has made groundbreaking discoveries across a number of programs that will be foundational for future work in biologicals,” said Michael Miille, CEO of Joyn Bio. “We are excited to take this platform to the next stage, with Bayer advancing key programs to the next level and working with Ginkgo to open our capabilities up to a broader set of commercial partners.”

The parties expect to sign a definitive agreement and proceed toward an efficient close, supported by ongoing integration planning efforts. More details and updates will be provided when available.

Find the full press release here along with all of the latest news from the Ginkgo team.

Optimizing the Brightness of Glowing Plants with Light Bio

Posted on by Jason Kelly

Leveraging Ginkgo’s engineering capabilities to optimize performance of Light Bio’s light-emitting plants

We’re excited to announce a new collaboration with Light Bio – a company creating bioluminescent plants for home and garden. The agreement will leverage Ginkgo’s plant cell assays for bioluminescence engineering. The aim: to improve the luminescent output and efficiency of the enzymes within Light Bio’s glowing ornamental plants.

Nothing captures the wonder of biology quite like seeing glowing plants in person. Our platform enables developers to imagine with biology and to design all types of cells, from bacteria and yeast to mammalian and plant cells. We’re so excited to bring this unique application onto our platform and to help Light Bio bring the magic of glowing plants to people.

Light Bio has discovered a new type of bioluminescence mechanism and uses synthetic biology to engineer plants to efficiently emit light. The original light emission pathway Light Bio uses in its glowing plants comes from bioluminescent mushrooms. The company is now focused on expanding its engineering capabilities to support the creation of glowing plants.

“We are excited to collaborate with Ginkgo toward additional multifold output and efficiency improvements powered by Ginkgo’s plant cell engineering capabilities across both individual enzyme and metabolic pathway improvements,” said Keith Wood, CEO, Light Bio.

What will you grow with Ginkgo?